title: Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
abstract: Answer questions and earn CME/CNE The eighth edition of the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) Staging Manual has been updated and improved to ensure the highest degree of clinical relevance and to improve its utility for patient evaluation and clinical research. Major changes include: 1) pathologically organ-confined disease is now considered pT2 and is no longer subclassified by extent of involvement or laterality, 2) tumor grading now includes both the Gleason score (as in the seventh edition criteria) and the grade group (introduced in the eighth edition criteria), 3) prognostic stage group III includes select, organ-confined disease based on prostate-specific antigen and Gleason/grade group status, and 4) 2 statistical prediction models are included in the staging manual. The AJCC will continue to critically analyze emerging prostate cancer biomarkers and tools for their ability to prognosticate and guide treatment decision making with the highest level of accuracy and confidence for patients and physicians. CA Cancer J Clin 2017;67:245-253. © 2017 American Cancer Society.
authors.affiliation: Associate Professor of Radiation Oncology, Department of Radiation Oncology, Stanford University, Stanford, CA.
authors.forename: Mark K
authors.initials: MK
authors.lastname: Buyyounouski
authors.affiliation: Director, Molecular Imaging Program, National Cancer Institute, Rockville, MD.
authors.forename: Peter L
authors.initials: PL
authors.lastname: Choyke
authors.affiliation: Section Head, Surgical Pathology, Robert J. Tomisch Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.
authors.forename: Jesse K
authors.initials: JK
authors.lastname: McKenney
authors.affiliation: Hematology/Oncology Section Chief and Professor of Radiation Oncology, Departments of Medicine and Urology, Tulane Medical School, New Orleans, LA.
authors.forename: Oliver
authors.initials: O
authors.lastname: Sartor
authors.affiliation: Chair, Department of Radiation Oncology, and Professor of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA.
authors.forename: Howard M
authors.initials: HM
authors.lastname: Sandler
authors.affiliation: Chair, Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN.
authors.forename: Mahul B
authors.initials: MB
authors.lastname: Amin
authors.affiliation: Chair, Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.
authors.forename: Michael W
authors.identifier: 0000-0002-3840-4161
authors.initials: MW
authors.lastname: Kattan
authors.affiliation: Chief of Urologic Oncology, Department of Urology, University of Washington, and Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Lin
mesh_terms: D006801:Humans; D008297:Male; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000145:classification / Q000000981:diagnostic imaging / Q000473:pathology*; D011859:Radiography
keywords: American Joint Committee on Cancer (AJCC); Gleason score; group grade; prognosis; prostate cancer; prostate-specific antigen; staging